




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/47	A1	(11) International Publication Number: WO 92/19243 (43) International Publication Date: 12 November 1992 (12.11.92)
--	-----------	--

(21) International Application Number: **PCT/US92/03895**(81) Designated States: **AU, CA, FI, JP, KR, NO.**(22) International Filing Date: **7 May 1992 (07.05.92)****Published**
With international search report.

(30) Priority data:

697,314	7 May 1991 (07.05.91)	US
876,200	30 April 1992 (30.04.92)	US

(71) Applicant: **THE LIPOSOME COMPANY, INC. [US/US];**
One Research Way, Princeton Forrestal Center, Princeton, NJ 08540 (US).(72) Inventor: **OSTRO, Marc, J. ; 23 West Shore Drive, Pennington, NJ 08534 (US).**(74) Agent: **BLOOM, Allen; The Liposome Company, Inc., One Research Way, Princeton Forrestal Center, Princeton, NJ 08540 (US).**(54) Title: **LIPOSOMAL PROSTAGLANDIN FORMULATIONS****HEART RATE VS. DURATION OF EXPERIMENT IN TREATED AND CONTROL DOGS**

(57) Abstract

A method of treating a cell activation/adhesion syndrome in mammals, including humans, by the administration of a prostaglandin associated with a liposome is disclosed. Such cell activation/adhesion syndromes may include reperfusion injury, septic shock, myocardial infarction, adult respiratory distress syndrome, rheumatoid vasculitis, systemic vasculitis, lupus, post traumatic shock, burn injury or restenosis after angioplasty. In a preferred embodiment, the prostaglandin is encapsulated in the liposomes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NI	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

LIPOSOMAL PROSTAGLANDIN FORMULATIONSFIELD OF THE INVENTION

5 This invention relates to liposomal prostaglandin formulations, and more particularly to the use of such formulations in the treatment of cell activation/adhesion syndromes.

BACKGROUND OF INVENTION

10

Prostaglandins and related products of eicosatrienoic acid, arachidonic acid and eicosapentaenoic acid metabolism belong to a class of compounds called "eicosanoids", because they are derived from 20-carbon essential fatty acids. See Gilman et al., eds., Goodman and Gilman's The Pharmacological Basis of
15 Therapeutics, Eighth Edition, Pergamon Press, New York, pp. 600-611 (1990), incorporated herein by reference, for a more complete discussion of the structure and synthesis of the eicosanoids, including the prostaglandins, prostacyclins (or prostaglandin I series), thromboxanes and leukotrienes. For purposes of the present discussion, the term "prostaglandins" shall be considered to include the related
20 eicosanoids identified as prostacyclins, thromboxanes, lipoxins and leukotrienes.

As discussed in Gilman et al., supra, the prostaglandins are substances found in essentially all human tissues and body fluids and produce a broad spectrum of effects embracing practically every biological function. They can be considered
25 analogs of a compound with the trivial name prostanoic acid, which structurally comprises a cyclopentane ring and two side chains. Prostaglandins generally fall into several main classes designated by letters and distinguished by substitutions on the cyclopentane ring. Prostaglandins of the E and D series are hydroxy ketones, while the F prostaglandins are diols. The D, E and F series compounds are products of the
30 metabolism of the G and H prostaglandins, and prostaglandins of the A, B and C classes are in turn derived from the corresponding E series compounds. Prostacyclin (PGI) and the thromboxanes are also derived from the G and H series prostaglandins. The main classes are further subdivided in accord with the number of double bonds in the side chains, indicated by subscript 1, 2 or 3. Of particular interest in the
35 present invention is prostaglandin E₁ ("PGE₁").

The prostaglandins have diverse physiological actions such as vasodilative action, improvement of peripheral blood circulation, and antilipolysis. Prostaglandins

are known to be therapeutically indicated in many conditions, such as ductus arteriosus, stimulation of uterine contractions leading to induction of labor at term as well as abortion, treatment of bronchial asthma, and suppression of gastric ulceration in animals.

Cell activation and adhesion is a significant problem affecting a wide variety of medical pathologies which shall be referred to herein collectively as "cell activation/adhesion syndromes". Certain cells have been found to exhibit elevated adhesiveness to other cells when adhesion sites on the cell are activated. For example, endothelial cells, such as vascular, plural, pericardial or abdominal endothelial cells, are activated by cytokines such as interleukin-1 (IL-1) or tumor necrosis factor-alpha (TNF-alpha) and/or bacterial endotoxins. In like manner, blood cells, particularly neutrophils and platelets, are activated by agents such as GM-CSF, bacterial endotoxins, bacterial chemoattractants, TNF-alpha, and the like, but especially by the C5a component of complement. Complement is a term for the thermolabile substance in serum that is destructive to certain bacteria and other cells that may be sensitized by a specific complement-fixing antibody. The activated neutrophils and platelets have adhesion sites by which the blood cells stick to each other or adhere to similarly activated endothelial cells. These adhesions result in the formation of clumps and the plugging of small blood vessels, such as those found in the lungs or heart, by adhering to the vascular endothelial cells of the blood vessels, and subsequent degranulation (or release of mediators of cell damage such as superoxide anion (O₂⁻) and proteolytic enzymes). These agents destroy the vascular endothelium and surrounding tissues and also cause capillary damage.

One manifestation of such plugging and degranulation is adult respiratory distress syndrome (ARDS), which is caused by blockages in the small blood vessels of the lungs and subsequent destruction of endothelial cells by activated neutrophils. Another manifestation is rheumatoid vasculitis or systemic vasculitis in which small blood vessels also suffer endothelial lesions. Tissue damage caused by cell activation/adhesion syndrome can also result in increased areas of necrosis in tissue damaged by ischemia or other destructive conditions such as burn injuries or traumatic shock. This is because the damaged tissue releases further amounts of adhesion activating agents, such as C5a, and this further causes additional damage both locally and systemically by the cell activation/adhesion syndrome effect, as discussed above. In effect, there is a destructive cycle of tissue damage releasing C5a and other activators, which cause further tissue damage through cell activation/adhesion syndrome and thus the release of more activator.

This cyclic effect is discussed in Abramson et al., "Complement Split Products and the Pathogenesis of SLE," Hospital Practice, 23(12):45-56 (1988), in regard to systemic lupus erythematosus (SLE). In this article it is postulated that intravascular
5 activation of complement triggers release of anaphylatoxins such as C3a and C5a and other complement split products into the circulation. The split products attract and activate inflammatory cells, such as neutrophils and platelets, causing them to aggregate, to adhere to vascular endothelium, to occlude small blood vessels and to release toxic mediators (such as O₂⁻, elastases, and metalloproteases). Activation of
10 circulating complement thus leads to an occlusive vasculopathy, degranulation of neutrophils, and widespread tissue injury.

Thus the cell activation/adhesion syndrome is characterized by the activation of cells by, for example, bacterial endotoxins and C5a. This activation causes the
15 release of toxic mediators which will destroy endothelium and surrounding tissue. Among the cell activation/adhesion syndromes to which the present invention is directed are, among others:

1. Reperfusion injury, such as that related to reperfusion of occluded blood vessels or incidental to transplant surgery or other surgery in which
20 blood flow is temporarily stopped.
2. Septic shock, such as infections which release bacterial endotoxins into circulation.
3. Myocardial infarction.
4. Adult respiratory distress syndrome (ARDS).
- 25 5. Rheumatoid vasculitis.
- 6 Systemic vasculitis.
7. Lupus, which involves circulating immune complexes.
8. Post traumatic shock, and
9. Burn injury.
- 30 10. restenosis after angioplasty

The effects of cell activation/adhesion syndrome are further discussed in regard to cardiac reperfusion injury in Seewaldt-Becker et al., "Effect of Anti-Adhesive Antibodies on Reperfusion Injury", in Springer et al., eds., Leukocyte Adhesion
35 Molecules, Springer-Verlag, New York, pp. 138-148 (1990). When there is a blockage in a blood vessel, there is inevitably damage to the endothelial cells of the affected blood vessel, as well as to the ischemic tissue downstream which is denied blood. When the occlusion is cleared, as by physical or chemical means, there is generally

further damage to the endothelial cells. Such damaged cells in turn induce activation in neutrophils and platelets. These activated cells then cause activation/adhesion cell damage, which is referred to as "reperfusion injury," after restoration of blood flow.

5

After reperfusion of an affected blood vessel it is important to restore blood flow as quickly as possible to prevent further tissue damage due to ischemia. However, it has been found that the increased cellular adhesion between neutrophils and endothelial cells inhibits rapid reperfusion in the previously ischemic region, sometimes referred to as the "no-reflow phenomenon". This phenomenon is also affected by the capillary blockage caused by clumping of activated neutrophils and platelets. Furthermore, the adhesion between neutrophils and endothelial cells may damage capillary tissue, allowing various mediators of cell injury released from damaged cells to reach coronary tissue, and thus cause further injury.

15

The effects of reperfusion injury and other cell activation/adhesion syndromes is also discussed in Springer et al., eds., "Adhesion in Disease and Therapy," Leukocyte Adhesion Molecules, Springer-Verlag, New York, pp. 85-156 (1990).

20

Prostaglandins, particularly PGE₁ have been found to have potential utility reducing the damage caused by the cycle of cell activation/adhesion syndrome. The same cells which have receptors for activating agents have also been found to have receptors for prostaglandins. It is believed that when prostaglandins, such as PGEs or PGIs, attach to these prostaglandin receptors they deactivate the sites of intercellular adhesion. The mechanism for this is believed to be an increased level within the cells of cyclic AMP via protein kinase A. However, regardless of the mechanism, the key point is that by activation of the prostaglandin receptors, the adhesion sites of the cell are deactivated. Thus, any chemicals capable of activating the prostaglandin sites on cells can break the destructive cycle of the various cell activation/adhesion syndromes. Such a chemical would not even have to be a prostaglandin, but merely a substance which can activate the cell prostaglandin receptors.

30

The use of prostaglandin to reduce reperfusion injury after the re-opening of occluded blood vessels, such as occurs in the treatment of coronary disease is discussed in Jugdutt et al., "Dissimilar of Prostacyclin, Prostaglandin E Prostaglandin Myocardial Infarct Size after Coronary Occlusion in Conscious Dogs," Circulation Research, 49(3):685-700 981). In this article both PGE₁ and PGI₂ were found to have

35

significant effect in reducing the infarct size in dogs which were reperfused after simulation of a myocardial infarction by placement of an occluder snare around a coronary artery. In the reported tests, the prostaglandin was administered via continuous arterial infusion over a six-hour period, resulting in the administration of a relatively large dose of the drug. A reason for this continuous infusion is that prostaglandins such as PGE₁ have an extremely short half life in vivo, and have to be continuously replenished to maintain an effective blood level. Furthermore, it is believed that the prostaglandin is rapidly inactivated when the blood passes through the lungs, which necessitates arterial infusion rather than a simpler intravenous administration. Additionally, the distribution of high levels of PGE₁ in vivo is known to induce systemic effects such as hypotension, tachycardia and diarrhea.

Therefore, there are problems associated in developing a prostaglandin-based drug. Prostaglandins are very unstable and as such are difficult to produce in a pharmaceutically acceptable formulation. At therapeutic doses, prostaglandins cause hypotension, reflex tachycardia, diarrhea, flushing, somnolence, and abortion in pregnant women; and 95% of the drug is cleared on first pass in the lung liver and kidney (mostly lung) thereby necessitating continuous infusions.

One method proposed for administering prostaglandin in smaller doses is presented in Mizushima et al., "A Multicenter Double Blind Controlled Study of Lipo-PGE₁, PGE₁ Incorporated in Lipid Microspheres, in Peripheral Vascular Disease Secondary to Connective Tissue Disorders," J Rheumatol., 14:97-101 (1987). This article, and the further references cited therein, discusses delivering the drug as "lipo-PGE₁", which is indicated to be in the form of "lipid microspheres", described as being "similar to liposomes". In fact, as described in U.S. Patent No. 4,493,847 issued to Mizushima et al., the "lipo-PGE₁" is a fat emulsion containing the PGE₁ and is not a liposome. However, such emulsions do not offer the stability of the liposome encapsulated PGE₁ used in the present invention.

Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single bilayer membrane) or multilamellar vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer). The bilayer is composed of two lipid monolayers having a hydrophobic "tail" region and a hydrophilic "head" region. The structure of the membrane bilayer is such that the hydrophobic (nonpolar) "tails" of the lipid

monolayers orient toward the center of the bilayer while the hydrophilic "head" orient towards the aqueous phase.

One class of liposomes are those characterized as having substantially equal
5 lamellar solute distribution as set forth in U.S. Patent No. 5,030,453; this class of liposomes is denominated as stable plurilamellar vesicles (SPLV) as defined in U.S. Patent No. 4,522,803 to Lenk et al., monophasic vesicles as described in U.S. Patent No. 4,588,578 to Fountain et al., and frozen and thawed multilamellar vesicles (FATMLV) wherein the vesicles are exposed to at least one freeze and thaw cycle, as
10 described in U.S. Patent No. 4,975,282 to Cullis et al., all incorporated herein by reference.

The lamellarity of a population of liposomes may be reduced and unilamellar vesicles may be produced using an extrusion process such as described in U.S.
15 Patent No. 5,008,050 to Cullis et al., incorporated herein by reference, in which liposomes are extruded under pressure through a filter.

In a liposome-drug delivery system, a bioactive agent such as a drug is entrapped in or associated with the liposome and then administered to the patient to
20 be treated. For example, see Rahman et al., U.S. Patent No. 3,993,754; Sears, U.S. Patent No. 4,145,410; Papahadjopoulos et al., U.S. Patent No. 4,235,871; Schneider, U.S. Patent No. 4,114,179; Lenk et al., U.S. Patent No. 4,522,803; and Fountain et al., U.S. Patent No. 4,588,578.

25 Lenk et al., U.S. Patent No. 5,082,664 filed May 18, 1988, issued January 21, 1992, incorporated herein by reference, and published as corresponding PCT Application Pub. No. WO 88/09170, December 1, 1988, discloses a method for encapsulating PGE₁, as well as other prostaglandins and eicosanoids, in liposomes.

30

SUMMARY OF THE INVENTION

In accordance with one aspect of the present invention there is provided a method of treating a cell activation/adhesion syndrome in an animal, including humans, comprising the step of administering an anti cell activation/adhesion
35 syndrome effective amount of a prostaglandin associated with a liposome. In a particular embodiment of this invention, the prostaglandin is encapsulated in the liposomes.

In a particular embodiment of the present invention, the method is directed to treating a cell activation/adhesion syndrome selected from the group consisting of:

1. Reperfusion injury, such as that related to reperfusion of occluded blood vessels or incidental to transplant surgery or other surgery in which blood flow is temporarily stopped.
2. Septic shock, such as infections which release bacterial endotoxins into circulation.
3. Myocardial infarction.
4. Adult respiratory distress syndrome (ARDS).
5. Rheumatoid vasculitis.
6. Systemic vasculitis.
7. Lupus, which involves circulating immune complexes.
8. Post traumatic shock, and
9. Burn injury.
10. Restenosis after angioplasty

In accordance with the present invention, it has been found that an effective amount of prostaglandin can be delivered in liposomal form to treat a cell activation/adhesion syndrome at a substantially lower dosage rate than when the prostaglandin is administered in free or unbound form. Without being bound by a particular theory or mechanism, it is believed that the liposomes are particularly attracted to the activated cells and adhere to the activated surfaces. The prostaglandin is then readily available at the site of injury to deliver its anti cellular adhesion action.

One theory for the attraction of liposomes to adhesion activated cells is that liposomes are opsonized by fibronectin and vitronectin in the blood. Opsonization is the process by which bacteria are altered such that they become more readily and efficiently engulfed by phagocytes. Thus opsonized liposomes would be more readily attracted to the activated neutrophils which express receptors for fibronectin and vitronectin, thereby delivering the associated prostaglandin to the affected sites.

As discussed above, because of the rapid metabolism of free prostaglandins in vivo, long continuous infusions of relatively large doses of these drugs have been required to maintain an effective blood level in the patient being treated. However, because of the hypotension, tachycardia and diarrhea caused by high blood levels of prostaglandin, it has not been feasible to administer effective amounts of

prostaglandins in free form. Furthermore, the high cost of prostaglandins makes it prohibitively expensive to administer such large dosages.

When prostaglandins are administered in the liposomal prostaglandin formulations of the present invention, a much smaller total dosage of the prostaglandin is required to obtain the desired bioactive effect. At the same time, because the prostaglandin is associated with the liposomes, the amount of free prostaglandin in the bloodstream is maintained at a level low enough to prevent or minimize the side effects such as hypotension or diarrhea. Thus, the method of the present invention provides for the effective administration of the prostaglandins at reduced cost and with reduced side effects. In fact, in many treatments, the present invention may provide the only effective way to administer the prostaglandins.

Liposomal-PGE₁ overcomes the problems associated with developing a prostaglandin -based drug. Due to the insertion of the drug into the liposome membrane, followed by lyophilization, the molecule is shielded from water and does not hydrolyze upon long term storage. Liposomal-PGE₁ can remain stable for 1.5 years at refrigerated temperatures and may be stable at room temperature for at least one year. Liposomal PGE₁ has also been effective in the prevention and treatment of ARDS and quite significantly showed no drop in blood pressure, increase in heart rate or diarrhea normally associated with free PGE₁ when given at therapeutic doses. One theory is that as PGE₁ is associated with a liposome its pharmacokinetic behavior is primarily dictated by the liposome and not the drug. Therefore, liposomal-PGE₁ is not cleared from the blood as quickly as free drug and can therefore be given as a quick infusion instead of being infused over several hours or days.

PGE₁ has been shown to be a potent inhibitor of both neutrophil and platelet aggregation, as well as the binding of these cells to activated vascular endothelial cells. It has the ability to both prevent inflammation, that is, prophylaxis, and to turn it off once it has been initiated by any of many factors, that is, treatment. Previously this potential has not been explored due to the aforementioned formulation, toxicologic and pharmacologic problems, which liposomal PGE₁ overcomes.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention there is provided a method of treating a cell activation/adhesion syndrome in an animal, including humans, comprising the step of administering an anti-cell activation/adhesion syndrome effective amount of a prostaglandin associated with a liposome. Such treatment shall be understood to encompass not only the treatment of present symptoms but also the prophylactic administration of such liposomal prostaglandin to prevent the development of such syndromes or to reduce their severity.

In a particular embodiment of the present invention, the method is directed to treating a cell activation/adhesion syndrome selected from the group consisting of:

1. Reperfusion injury, such as that related to reperfusion of occluded blood vessels or incidental to transplant surgery or other surgery in which blood flow is temporarily stopped,
2. Septic shock, such as infections which release bacterial endotoxins into circulation,
3. Myocardial infarction,
4. Adult respiratory distress syndrome (ARDS),
5. Rheumatoid vasculitis,
6. Systemic vasculitis,
7. Lupus, which involves circulating immune complexes,
8. Post traumatic shock, and
9. Burn injury.
10. Restenosis after angioplasty

Tissue destruction as a result of inflammation has been implicated in the pathogenesis of a wide variety of conditions including, among others, reperfusion injury, adult respiratory distress syndrome (ARDS), septic shock, inflammatory bowel disease and rheumatoid arthritis. The inflammatory process involves a complex sequence of events terminated by the release of destructive oxygen species (O_2^-) and degradative enzymes from neutrophils, white blood cells considered normally to be the body's first line of defense against invading pathogens. In the inflammation process, the normal immune response is activated but the target is host tissue instead of bacteria.

The inflammatory process can be divided into four parts, insult, cell-activation, cell-cell adhesion, and cellular release of mediators of tissue damage. The seminal insult varies from disease to disease. For example, ARDS is induced by factors such as massive trauma or septicemia, cardiac reperfusion injury is caused by the

dissolution or dislodging of a clot blocking the coronary artery, restenosis is the result of vascular damage stemming from angioplasty, and septic shock often results from certain types of blood borne infections.

5 Once an insult occurs, humoral mediators such as interleukin 1 (IL-1), tumor necrosis factor (TNF), peptides produced as a result of complement activation (C5a and C3a, also called anaphlotoxins), and bacterial endotoxins are released into the blood, activating neutrophils and platelets (both white blood cells) and endothelial cells which line the blood vessel walls. All of these cells have specific receptors for
10 each activator. Once binding between the activator and its receptor occurs, the cell switches to a "turned on" or activated state. One of the major changes that occurs on activated cells is the expression of either newly produced receptors or the activation of dormant receptors already present on the cell surfaces. Many such receptors exist, each with a proclivity for a complementary molecule (ligand) on
15 another cell. These receptor-ligand pairs can mediate an adhesion between neutrophils and endothelial cells, neutrophils and neutrophils, platelets and endothelial cells, and platelets and platelets (platelet aggregation).

20 The last step in the inflammatory process involves the release of O₂-and degradative enzymes from either activated neutrophils or platelets (mostly neutrophils) bound to endothelial cells lining the blood vessel walls. The release of these factors can destroy the vascular endothelium allowing the extravasation of inflammatory cells into the surrounding tissue resulting in tissue destruction.

25 Platelet aggregation, the binding of platelets to each other, can be triggered by many of these same processes. However, instead of the release of O₂- or degradative enzymes, platelet aggregation may result in the formation of clots which may block arteries resulting in reocclusion and /or reinfarction.

30 If the lungs are the main organ that is affected, the condition is referred to as ARDS. If there are other signs present, such as a sharp blood pressure drop, the condition is known as shock. Sepsis/trauma syndrome refers to the broad group of patients suffering from insults such as trauma and infection in whom factors such as TNF, IL-1, etc. are released, with the possibility of shock and organ failure ensuing.

35 When patients are subject to the insults that can lead to ARDS, such as, to trauma, burns, sepsis, aspiration and hyperoxia, many organs in the body other than the lungs can be affected. The causes and clinical courses of this condition can vary

widely. For example, in the case of a patient with a severe infection endotoxin is released from the bacterial cell walls, the inflammatory cascade is initiated, leading to septic shock. Again, as sepsis/trauma syndrome is not limited in causation to infections it is possible that no endotoxin is involved, but nonetheless, the release of factors such as TNF, IL-1 complement and leukotrienes is triggered. The logic and biology involved in the sepsis/trauma syndrome is comparable to that of ARDS, the only difference being that the final target of the cascade involves multiple organs, not just the lungs.

Angioplasty is a technique whereby a balloon is inserted into an occluded artery and inflated in order to open blocked blood vessels. Although this technique has become quite routine in the management of coronary artery disease in the six month period following this procedure, over 33% of the treated patients experience restenosis, or reocclusion of the previously opened blood vessel. It is thought that this condition starts with injury to the vascular endothelium which often results from the balloon procedure. The exposed extracellular matrix will rapidly bind to several layers of activated platelets. Once platelets bind, they will release a variety of growth factors which will result in the proliferation of smooth muscle cells underlying the vessel to the point where the vessel becomes reoccluded. By preventing platelets from binding to the extracellular matrix, one can disrupt the cascade of events resulting in restenosis. Thus, acute administration at the time of the angioplasty procedure of a drug that prevents platelet binding could prevent restenosis.

Recently, De Servi et al., European Heart Journal, "Prostaglandin E administration in unstable angina patients undergoing PTCA: preliminary results". August 1990., published the results of a clinical trial in patients with unstable angina who were given an intracoronary infusion of PGE₁ prior to and following angioplasty. The drug was infused over a 24-hour period. The results of this study showed that the rate of restenosis six months after angioplasty in the PGE₁-treated group was reduced by almost 50% versus the untreated control group, even though the treatment with PGE₁ only lasted 24 hours.

Acute myocardial infarction (more commonly referred to as a heart attack) refers to a blockage of the blood supply to the muscles of the heart, usually caused by a blood clot. If the blood is prevented from reaching the heart for too long, the patient will die. When an occlusion of the coronary artery occurs, the patient is either treated with a fibrinolytic agent, such as tissue plasminogen activator (tPA) or streptokinase, to dissolve the clot, or the blockage may resolve itself. In both

instances, blood flow is resumed to the ischemic (oxygen-deprived) region of the heart. This reflow of blood into the heart is called reperfusion. While reperfusion is necessary to save the patient's life, it causes further injury to the heart muscle called reperfusion injury. Reperfusion injury is known to be the end result of the
5 inflammatory cascade.

In addition to the problem of reperfusion injury following clot removal, patients suffering from a myocardial infarction may suffer from other secondary problems. For example, after the normal blood flow is restored to the heart, both neutrophils
10 and platelets are activated. Activated platelets often adhere to one another and begin to reocclude the coronary artery, resulting in a situation where the rate of blood flowing to the heart decreases over time. In some cases, complete reocclusion will occur. PGE₁, in addition to preventing neutrophil binding to endothelial cells, prevents platelet aggregation and reduces, if not eliminates, the no reflow
15 phenomenon.

Sharma et al., The American Journal of Cardiology, "Intracoronary Prostaglandin E₁ Plus Streptokinase in Acute Myocardial Infarction", page 1161, Dec. 1986, vol. 58, has shown in a clinical setting of acute myocardial infarction that
20 administration of PGE₁ by slow intracoronary infusion together with intracoronary streptokinase provides positive clinical results when compared with a control group taking intracoronary streptokinase alone. The results showed decreased time to reperfusion, reduced dose of streptokinase required, increased percentage of vessels patent after 10 days, and higher ejection fractions. Drawbacks of the study are that
25 the drug must be given by slow intracoronary infusion which is cumbersome and requires specialized facilities and highly trained personnel. Also this approach requires careful titration of the dose of PGE₁ so that significant drops in blood pressure can be seen.

30 Liposomal PGE₁ is unique in being able to effect both neutrophils and platelets substantially equally.

It has been found that the extracellular release by neutrophils of mediators of inflammation can be modulated by the elevation or depletion of intracellular stores of
35 cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Elevation of cAMP reduces release of mediators of inflammation whereas increases in the levels of cGMP enhances the excretion of those mediators. cAMP is sometimes referred to as the "universal off-switch" since increasing intracellular levels

of cAMP can turn off inflammation, regardless of the factor that initially turned it on. Importantly, some prostaglandins such as PGE₁ elevate cAMP, thus providing the rationale for using PGE₁ as an anti-inflammatory agent. PGE₁ can be thought of as an agent that can activate the "universal switch off". It has now been shown in vitro
5 that PGE₁ inhibits the binding of neutrophils and platelets to themselves, as well as to endothelial cells, by preventing the activation of the receptors necessary to mediate cell-cell adhesion. This inhibition is coincident with the elevation of intracellular cAMP. Without cell-cell binding, cofactors such as O₂- and various degradative enzymes cannot be released, and tissue damage is eliminated. therefore, PGE₁
10 actually acts as a potent anti-inflammatory agent. It can both prevent inflammation and turn it off, regardless of whether the mediating factor is IL-1, TNF, complement, leukotrienes or others.

The liposomes used in this invention present bioactive eicosanoids, particularly
15 prostaglandins, in association with liposomes. Such association may include the entrapment of the prostaglandin in the liposomes, as well as the association of the prostaglandin with the external or internal membrane surface of the liposomes.

Among the preferred prostaglandins for use in the method of the present
20 invention are the prostaglandins of the E series (PGEs) and the I series (PGIs or prostacyclins), with prostaglandin E₁ showing particular utility in the treatment of cell activation/adhesion syndromes. Such prostaglandins have been found to inactivate the adhesion receptor sites on cells. As discussed above, it is theorized that the prostaglandin activates a prostaglandin receptor site on the cells which in
25 turn causes the deactivation of the adhesion sites. This result may also be achieved by non-prostaglandin compounds which are effective prostaglandin site activators. That is, such compounds may be considered as being "prostaglandin-effective" for purposes of the method of the present invention. For this reason, the term prostaglandin in regard to the method of the present invention is considered to
30 include such prostaglandin-effective compounds.

The "anti-cell activation/adhesion syndrome effective amount" of the prostaglandin associated with a liposome is readily determinable by one skilled in the art. For a particular syndrome, one would conduct dose-ranging trials for the
35 selected liposomal prostaglandin to determine an effective, non-toxic dosage level. For the anti-perfusion injury treatment discussed in Example 3 below, dose-ranging trials were used to determine a suitable dosage was determined to be about 0.5 ug

PGE₁ per kg of animal weight. Such dose-ranging may be readily conducted in the same manner for other syndromes.

The mode of administration of the preparation may determine the sites and
5 cells in the organism to which the compound will be delivered. The liposomes of the present invention can be administered alone but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. The preparations may be injected parenterally, for example, intra-arterially or intravenously. For parenteral
10 administration, they can be used, for example, in the form of a sterile aqueous solution which may contain other solutes, for example, enough salts or glucose to make the solution isotonic. The prostaglandin E₁ liposomes of the present invention, for example, may be given parenterally at a dosage of about 0.5 ug per kg body weight, over a ten-minute period, once or twice a day. Other uses, depending upon
15 the particular properties of the preparation, may be envisioned by those skilled in the art.

The liposomes of the invention may be formed by any of the known methods for forming liposomes, and may be loaded with bioactive agent according to the
20 procedures disclosed in U.S. Patent No. 5,082,664, Lenk et al., as discussed above and incorporated herein by reference. In addition, a similar process for ionizable antineoplastic agents is discussed in Bally et al., PCT Application No. 86/01102, February 27, 1986 and incorporated herein by reference.

25 In general, any of the methods for forming liposomes mentioned in the Background of the Invention may be used in the practice of the invention, but methods that form unilamellar vesicles are preferred, most preferably large unilamellar vesicles. A preferred method for forming these unilamellar vesicles is the association of bioactive agent (drug, specifically prostaglandin) with the lipid in
30 ethanol similar to the technique of Batzri et al., *Biochim. et Biophys. Acta.*, 298:1015 (1973) using a transmembrane concentration gradient as disclosed in Bally et al. (*supra*) to load the bioactive agent.

In this technique, lipid and prostaglandin are co-dissolved in an aqueous-
35 miscible organic solvent such as ethanol, then added slowly to a first aqueous solution. Optionally, a preservative such as butylated hydroxytoluene (BHT) may be admixed with the lipid in the solution. The first aqueous solution should include a drying protectant and may additionally include a buffer, such as acetate, citrate or

phosphate. The drying protectant may be a saccharide, such as sucrose, maltose, lactose or dextrose, or a combination of saccharides such as either sucrose, maltose, lactose or dextrose with mannitol. Maltose is preferably used. Other saccharides may include, for example, mannose, galactose, raffinose, or trehalose. Alternatively, 5 other protectants such as dextran, albumin, and poly(vinyl alcohol) may be used. The buffer may be relatively acidic, that is, having a pH less than about 5.0.

The resulting liposome dispersion may be size-reduced to a more homogenous population, for example, by extrusion through a filter, preferably of 100 nm pore size, 10 the filter being of either the straight path or tortuous path type. A preferred filter for use in this process is an aluminum oxide porous film such as the Anopore™ filters made by Anotec Separations. These filters are discussed in copending U.S. Patent Application Serial No. 07/593,200, filed October 5, 1990.

15 Such a population of liposomes may be formed by the extrusion procedures of U.S. Patent No. 5,008,050 to Cullis et al., previously incorporated herein by reference. Such extrusion procedures, wherein the liposomes are passed through a filter under pressure, allow the formation of homogenous populations of liposomes with regard to size. The extrusion may be performed by one or several passes through a filter; for 20 example a straight-through membrane filter (e.g., a NucleporeR polycarbonate filter) or a tortuous path filter (e.g., a NucleporeR Membrafil™ filter (mixed cellulose esters)). When the liposomes are passed more than one time through the filter, the number of passes required will be determined by that necessary to achieve the desired liposome size.

25 The filter sizes used in the invention are chosen according to the desired size of the final liposome product. In the present invention, liposomes having an average diameter of less than about 200 nm are preferred. The individual liposomes of the present invention are preferably less than about 500 nm in diameter, and are 30 preferably 100 nm to 300 nm in diameter. In the present invention, liposomes of less than about 200 nm diameter are particularly preferred, because liposomes of this size are known to pass through the capillary bed of the lung and are therefore able to pass through to other organs and tissues. Therefore, a filter having a pore size of about 100 nm is chosen for use in the extrusion step.

35 Other methods for size-reducing the liposomes to a homogenous size distribution as defined hereinabove are ultrasonic exposure, the French Press

technique, hydrodynamic shearing, homogenization using for example, a colloid mill or Gaulin homogenizer, or other size reduction techniques.

5 The resulting size-reduced liposomes are desirably homogenous with regard to size, preferably having a Gaussian size distribution about a mean diameter of less than about 200 nm, with a range of about 20 to about 500 nm. This size-reduced product may be diluted with additional aqueous solution, dried, and stored until use. The size-reduced liposomes may also be sterile filtered, such as by passage through a 220 nm Millipak filter (Millipore, Inc., Bedford, MA).

10

Immediately prior to use, the lyophilized product may be reconstituted with an aqueous solution having a pH relatively acidic pH, that is, less than about 5.0. Such an adjustment of the pH of the external medium will partition the bioactive agent (prostaglandin) into and/or through the liposome membranes, effectively loading the
15 prostaglandin into the liposomes.

The prostaglandin-associated liposomes may be dehydrated or lyophilized by any method known in the art. This drying procedure requires the addition of a drying protectant to the liposome suspension. This drying protectant prevents the
20 rearrangement of the lipids in the liposome, so that the size and contents are maintained during the drying procedure and through rehydration. Appropriate qualities for such drying protectants are that they be strong hydrogen bond acceptors, and possess stereochemical features that preserve the intramolecular spacing of the liposome bilayer components. It has been found that one group of
25 drying protectant, the saccharide sugars, when included in the liposome formulations, are especially useful at maintaining the liposome particle size after rehydration. This specific group of saccharides comprises, for example, dextrose, sucrose, and maltose, which may be used at about 5 to about 20 percent, preferably at about 10 percent by weight of the aqueous phase. Other saccharides which may
30 be employed are mannose, galactose, raffinose, trehalose, lactose, or triose sugars. Mannitol may be used in conjunction with any of the saccharides, but it has surprisingly been found that when used alone, mannitol does not succeed in maintaining liposome size. Mannitol may be used in concert with the saccharides in about a 0-2% concentration, preferably a 1% concentration. The total concentration
35 of saccharide used ranges from about 5% to about 20%, preferably 10% to 12%, most preferably about 10%. Additional preservatives such as BHT or EDTA in the formulations at, for example, 5 mg BHT per mL of ethanol, and, for example, 0.01%

EDTA in 10% dextrose may also be included. Other substances such as urea, albumin, dextran, or poly(vinyl alcohol) may also be used.

The dehydration or lyophilization of the liposomes of the present invention may be performed by any methods known in the art for dehydrating or lyophilizing liposomes. For dehydration, for example, the liposomes may be dried according to the procedures of Janoff et al., U.S. Patent No. 4,880,635, incorporated herein by reference.

Regardless of the dehydration or lyophilization technique, the procedure reduces the aqueous content of a sample to less than about 2%, preferably to less than about 1%. Using the current methods, the liposomal prostaglandin formulation is lyophilized to the point of containing 0-2% aqueous content, and preferably 0-1% aqueous (water) content.

The lyophilized prostaglandin-liposome formulations can be stable for at least one year when stored at 6°C or 25°C. Stability studies using high pressure liquid chromatography (HPLC) analysis of the formulation have shown that after storage at 6°C for one year, no degradation products of the PGE₁ were present.

When the lyophilized liposomes are to be used, rehydration is accomplished by adding an aqueous solution, e.g., distilled water, water for injection (WFI), or buffer or aqueous solution of appropriate pH, as described above, to the liposomes. The liposomes can be then resuspended into the aqueous solution by gentle mixing. The rehydration can be performed at about 25°C.

The following examples are given for purposes of illustration only and not by way of limitation on the scope of the invention.

EXAMPLE 1

A 1500 mL batch of liposomal PGE₁ was made up of the following components:

Ingredient	Per 1500 mL	Per mL
Egg phosphatidylcholine (EPC)	7.06 g	4.4 mg
Maltose monohydrate	150.0 g	100 mg
Ethanol (anhydrous)	8.38 mL	0.00558 mL
Butylated hydroxytoluene (BHT)	45 mg	0.03 mg
PGE ₁	15 mg	0.01 mg
Water for Injection, USP	qs 1500 mL	

Preparation:

1350 mL of water for injection was added to a beaker and set with a nitrogen
5 sparge for at least 30 minutes. The 150 g. of maltose (J.T. Baker, Phillipsburg NJ) was
added to the water and mixed until dissolved, with the nitrogen sparge continued.
This produced 1440 mL of mixture at a pH of 4.81.

10 In another beaker, the 7.06 g of egg phosphatidylcholine (EPC) (Nippon Oil and
Fats, Hyogo, Japan) were combined with 6 mL of ethanol (anhydrous) and mixed until
dissolved, and the 45 mg of BHT was added and mixed until dissolved. To this
mixture, the 15 mg of PGE₁ was added and mixed until dissolved, the remaining 2.37
mL of ethanol being used to rinse any remaining PGE₁ in the weighing container into
the mixture.

15

The ethanol solution was drawn into a 10 mL capacity glass syringe and
injected through a 14 gauge cannula slowly over a period of 11 minutes into the
maltose solution with rapid mixing and continued nitrogen sparge. Upon addition of
the ethanol/lipid mixture, the solution became cloudy, indicative of the formation of
20 liposomes. The suspension was then diluted to a final volume of 1500 mL with the
remaining water for injection.

The liposome dispersion was then extruded 3 times through a 0.2 μ m poresize
NucleporeR polycarbonate straight through path type filter (Nuclepore, Pleasanton
25 CA), followed by 5 extrusions through a corresponding 0.1 μ m filter. The particle size
of the resulting liposomes was determined to be 0.169 μ m (S.D. 0.041 μ m), using
quasi-elastic light scattering (QELS) (Nicom Particle Sizer). The sized liposome
dispersion was then passed through a 0.22 μ m Millipak sterilization filter. Finally,
10.5 mL aliquots of the dispersion were filled into vials and lyophilized according to
30 the procedures set forth as Example 2 to form a lyophilized product, which can be
used immediately or stored for future use.

The lyophilized product was rehydrated with 10 mL of 0.01 M acetate buffer (pH
4.3), with the resultant suspension having pH of about 4.3. Entrapment of the PGE₁
35 in the liposomes was determined by HPLC, and it was found that at least 98 percent
of the available PGE₁ was entrapped in the liposomes, at a concentration of about 9.0
 μ g PGE₁ per mL of rehydrated suspension.

EXAMPLE 2Lyophilization process

Split-top, butyl-rubber stoppered, Flint lyophilization vials of 50 mL capacity
5 were filled with 10.5 mL of aqueous-suspended liposomes, containing PGE₁. These
vials were placed on shelves in the lyophilizer (PV-24 Stokes Lyophilizer). The vials
were held at 0°C for 1.5 hours. The shelf temperature was then decreased to -45°C at
a rate of 0.8°C per minute, and held for 1 hour, after which a vacuum of 100 um Hg
10 was applied. The shelf temperature was then increased to -28°C at a rate of 0.5°C per
minute, while continuing the vacuum at 100 ug Hg.

The vials were held at -28°C for 50 hours at 100 um Hg vacuum. The shelf
temperature was then increased to +25°C at a rate of 0.5°C/min and held for 22
hours. The vials were then stoppered under partial vacuum.

15

Acute Myocardial InfarctionEXAMPLE 3

20

In vivo test of liposomal PGE₁

The rehydrated liposomes of Example 1 were tested in vivo as a means of
reducing reperfusion injury incidental to the treatment of myocardial infarction
25 resulting from occluded blood vessels. A total of 53 conditioned 25-35 kg dogs were
studied in the dose-ranging trials and the infarction study. Dogs were excluded from
analysis for the following reasons: extensive collateralization to the infarct zone (4),
heart worms at necropsy (1) and cardiac arrest during occlusion (1). Forty dogs
survived of which 27 were suitable for analysis: 7 dogs each in the control, liposomal
30 PGE₁ and liposome-control (empty liposomes) groups and 6 dogs in the PGE₁-control
(free PGE₁) group.

First, dose-ranging trials were conducted to determine a suitable dosage for use
in the myocardial infarction studies. Incremental doses of liposomal PGE₁ were given
35 while heart rate, mean arterial pressure, cardiac output and pulmonary capillary
wedge pressure were measured. Blood samples were also taken at intervals for
platelet aggregation studies (Figure 1). Doses greater than 2.0 ug/kg delivered as a
bolus over 10 to 20 minutes produced a marked tachycardia and transient

hypotension with a significant increase (doubling) in cardiac output. Platelet aggregation was partially inhibited at 0.1 ug/kg and totally inhibited at 0.6 ug/kg. A dose of 0.5 ug/kg delivered over 10 minutes seemed to increase the heart rate and cardiac output only slightly. In order to optimize the potential results, it was elected to give two doses of liposomal PGE₁ of 0.5 ug/kg each. One injection was administered just after occlusion of the infarct-related artery and the other just prior to reperfusion. This regimen should insure an effect throughout the period of ischemia and initial period of reperfusion. The effect of the liposomal PGE₁ appeared to persist for some time after administration. This observation is significant to reocclusion after reperfusion and restenosis following angioplasty which are directly related to platelet aggregation and adherence to endothelial cells and extracellular matrix.

The effects of liposomal PGE₁, free PGE₁, empty liposomes and a control group on heart rate were studied. The test dogs were anesthetized with sodium pentobarbital and maintained with intravenous pentobarbital and InovarR (droperidol/fentanyl). Arterial occlusion was simulated by ligating the left descending aorta artery. Ten minutes after occlusion, 0.5 ug/kg liposome-bound PGE₁ was administered intravenously over ten minutes into a first group of dogs, with a second group of control animals maintained without treatment. The liposome infusion tended to cause an increase in heart rate which was counteracted, in part, by administration of small amounts of additional Inovar. Tests showed no major differences in heart rate throughout the experiment between the control and treated animals. One hundred minutes after occlusion, a second dose of 0.5 ug/kg was administered over ten minutes. After 2 hours, the ligature was removed, causing an acute reperfusion of the blood vessel. Two hours later, the dog was euthanized, and the heart examined for myocardial infarction damage. The results are summarized in Figure 2. The group receiving free PGE₁ exhibited a significant rise in heart rate after the initial dosage and continuing until reperfusion. This rise was not noted in any of the remaining 3 groups of animals. This rise has been attributed to compensatory tachycardia due to vasodilation.

A total of seven dogs were included in the control group, and seven dogs were treated with liposomal PGE₁. During the test period, mean aortic pressure remained relatively constant, and there was no significant difference between the control and treated groups. Mean left arterial pressure increased in each group after occlusion, but there were no significant differences between the groups. Results are summarized in Figure 3.

As anticipated, myocardial blood flow, as measured by 15 μ m radioactive microspheres, demonstrated a significant decrease in all groups of animals after occlusion. There was no significant improvement in collateral blood flow after liposomal PGE₁ infusion in the test animals suggesting that the microvascular vasodilatory effects of liposomal PGE₁ were minimal.

With reperfusion blood flow increased significantly higher in treated dogs compared to control animals. Examination of the hearts showed that the myocardial infarct size, expressed as a percent of region at risk (i.e. area of low flow during ischemia), appeared reduced by about 50% in the dogs treated with liposomal PGE₁, as compared to the untreated control dogs. In addition, the administration of liposomal PGE₁ resulted in an almost total inhibition of platelet aggregation in the blood.

Figure 4 summarizes the results on the four groups of dogs receiving either liposomal PGE₁, free PGE₁, empty liposomes or saline. The liposomal PGE₁ was given in two 0.5 ug/kg infusions over 10 minutes each for a total dosage of 1.0 ug/kg. Free PGE₁ was continuously infused over 90 minutes at .1 ug/kg/minute or at a total dosage of 9 ug/kg.

Tests were also conducted to measure the white blood cell infiltration into the ischemic tissue of the heart. Immediately following extraction of the heart from the animals, samples were obtained from the 1) infarct zone, 2) border zone of the infarct zone within the risk region, 3) risk (ischemic) zone, and 4) control zone outside the region at risk. (The region at risk was the portion of the heart supplied by the occluded blood vessel.) The tissue was flash frozen using liquid nitrogen, and kept at -70°C until analyzed. Myeloperoxidase (an enzyme found only in neutrophils) activity was subsequently analyzed for each of the four zones in each animal heart. Initially, six control animals were tested in this manner, although one of these (CONT 4 in the table) was considered aberrant throughout the test, but was included in the tabulation for completeness. Only four of the animals treated with liposomal PGE₁ (LIPO 1-4) were included in this portion of the study. The results are presented in tabular form in Table 1, with the level of myeloperoxidase expressed in arbitrary units of enzyme for comparative purposes:

TABLE I

MYELOPEROXIDASE RELEASED FROM MYOCARDIAL TISSUES

DOG	ZONE			
	1	2	3	4
	22.8	17.8	1.1	- 1.3
CONT 1				
CONT 2	18.2	0	6	0
CONT 3	23.3	29.0	17.9	0.7
CONT 4	0	0	0	0
CONT 5	23.5	24.4	19.6	3.9
CONT 6	2.7	3.0	1.2	1.7
MEAN	15.1	12.4	7.6	1.3
STD	10.9	13.0	8.9	1.5
LPO 1	1.7	0	0	0.6
LPO 2	1.3	-	0	0.5
LPO 3	-	0	0	0
LPO 4	2.7	0.5	0	0.2
MEAN	1.9	0.2	0	0.3
STD	0.7	0.3	0	0.3

Additional dogs were tested in each group. Figure 5 summarizes the results of the totality of dogs suitable for analysis in each of the four groups tested.

In the above table, a dash indicates no measurement was made for that particular value.

Adult Respiratory Distress Syndrome (ARDS)

ARDS is a condition secondary to a variety of insults including, but not limited to, trauma, burns, sepsis, aspiration and hyperoxia. The condition is characterized by interstitial edema due to capillary injury. Once the lungs fill with fluid, breathing becomes difficult, and 5-60% of the patients die. The sequence of events leading to this catastrophic conclusion can vary depending upon the nature of the initial insult. Factors such as C3a, C5a, IL-1 and TNF activate the neutrophils. The mode of action of PGE₁ is independent of the mechanics of cellular activation. In the presence of

PGE₁, neutrophils cannot be activated, and if they are already activated they will be turned off, thereby preventing the disease.

Studies were conducted on rodent models for ARDS where lung injury had been induced by either thermal injury or by direct intratracheal injection of IL-1. As noted in the following examples, doses of liposomal-PGE₁ prevented the leak of fluid into the lung and significantly reduced the influx of neutrophils into the lung.

EXAMPLE 4

10

In vivo tests for prophylaxis of ARDS:

The rehydrated liposomal PGE₁ of Example 1 was tested in vivo as a prophylactic to the onset of adult respiratory distress syndrome (ARDS). Test rats were divided into three groups containing seven or eight animals each and treated with either 8ug/kg of liposomal PGE₁ or saline simultaneous with and one after thermal injury (by immersion in 70°C water for 45 seconds). The first group was treated with liposomal PGE₁, the second group was not treated with the liposomal PGE₁, but was subjected to the same trauma and the third group was neither treated nor traumatized. One hour prior to sacrifice of the rats, 125 I-albumin was injected intravenously as a marker for fluid leak into the lung. Four hours after thermal injury the animals were sacrificed.. The results of the study are summarized in Figure 6.

An effect of such traumatization is known to be the onset of ARDS, as evidenced by an increased level of albumin in the lungs of affected animals. The untreated traumatized animals all exhibited elevated levels of albumin in the lungs. Furthermore, six out of these seven test animals died. The level of albumin in the animals treated with liposomal PGE₁ was found to be about as low, or even lower, than the levels in the untraumatized control group. Furthermore, none of the seven PGE₁ treated animals died as a result of the trauma. These results show the effectiveness of liposomal PGE₁ as a prophylactic to the onset of ARDS.

EXAMPLE 5

35 In vivo tests for treatment of ARDS induced by intratracheal injection of IL-1 :

Intratracheal instillation of recombinant IL-1 induces a neutrophil influx and lung injury in rats (Figure 7). Liposomal PGE₁ treatment will decrease IL-1 induced

lung injury and neutrophil influx. 50 ng of commercially available interleukin 1 (IL-1) or saline (in the control group) was instilled into the trachea of rats inducing neutrophil infiltration into the lungs and leak of fluid into the alveoli. Intravenous treatment, 6 ug/kg, of either rehydrated liposomal PGE₁ of Example 1, free PGE₁ or empty liposomes was administered 2.5 hours after IL-1 instillation in rats having received the IL-1. Of the rats analyzed 40 received only saline, 54 received IL-1 and were untreated, 6 received IL-1 and were treated with liposomal PGE₁, 6 received IL-1 and were treated with empty liposomes, and 6 received IL-1 and were treated with free PGE₁.

10

Four and a half hours after the IL-1 was given, after many neutrophils had already infiltrated into the tissue, the rats were injected with 125 I albumin as a marker into the bloodstream. A half an hour after the albumin was injected the animals were sacrificed, the lung removed and the leak of fluid into the lung was quantitated by determining the amount of isotope in the tissue. A lung leak index was calculated based on the count per minute (cpm) of labeled 125 I-albumin in the lung divided by the amount of labeled 125 I-albumin in the bloodstream. The lung leak is expressed on the Y-axis of Figure 7. As noted in Figure 7, instillation of IL-1 without treatment caused a 2.5-fold increase of lung leak above sham or animals given saline. However, when liposomal PGE₁ treatment was given after instillation of IL-1, the lung leak index was equal to that seen in the sham control. Importantly, treatment with neither the free PGE₁ nor the empty liposomes had any effect on lung leak.

25 This sequence of events represents that which might occur in a clinical setting. Injury was induced, and treatment was initiated at a later time after the appropriate diagnosis was made.

30 The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expression of excluding any equivalents of the features described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.

CLAIMS

What is claimed is:

- 5 1. A composition comprising a prostaglandin associated with a liposome
manufactured for treating a cell activation/adhesion syndrome in a mammal.
2. The composition of claim 1 wherein the prostaglandin is associated by being
encapsulated in said liposome.
- 10 3. The composition of claim 1 wherein the mammal is a human.
4. The composition of claim 1 wherein the cell activation/adhesion syndrome is
selected from the group consisting of reperfusion injury, septic shock, myocardial
15 infarction, adult respiratory distress syndrome, rheumatoid vasculitis, systemic
vasculitis, lupus, post traumatic shock, burn injury and restenosis after angioplasty.
5. The composition of claim 4 wherein the cell activation/adhesion syndrome is
reperfusion injury.
- 20 6. The composition of claim 4 wherein the cell activation/adhesion syndrome is
adult respiratory distress syndrome.

1/7





FIG. 1

2/7

FIG. 2 HEART RATE VS. DURATION OF EXPERIMENT IN TREATED AND CONTROL DOGS



3/7

FIG. 3

LEFT ATRIAL PRESSURE VS DURATION OF EXPERIMENT

□ L-PGE₁ N=7 △ CONTROL N=7 ○ PLAIN-LIPO N=6 ◇ PGE₁ N=6






FIG. 4



5/7


FIG. 5 MYELOPEROXIDASE RELEASE FROM MYOCARDIAL TISSUE



6/7

FIG. 6


LUNG INJURY IS PREVENTED AFTER SKIN THERMAL
INJURY IN RATS PRETREATED WITH LIPOSOMAL PGE₁



*P<0.06

7/7

FIG. 7
EFFECT OF EMPTY LIPOSOMES OR FREE-PGE₁
ON LUNG LEAK IN RATS GIVEN IL-1 INTRATRACHEALLY



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/03895

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 31/47

US CL :424/450

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. :

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,820,732 (SHELL) 11 April 1989, Abstract and column 11, lines 57-68.	1-6
X.P	US, A, 5,082,664 (LENK) 21 January 1992, Abstract.	1-6

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A document defining the general state of the art which is not considered to be part of particular relevance	* X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E earlier document published on or after the international filing date	* Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* Z document member of the same patent family
* O document referring to an oral disclosure, use, exhibition or other means	
* P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 14 JULY 1992	Date of mailing of the international search report 13 AUG 1992
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE	Authorized officer In GOLLAMUDI KISHORE Telephone No. (703) 308-2351 NIGHTINGALE NGUYEN NIGHTINGALE NGUYEN INTERNATIONAL DIVISION